StockData

Insmed vs Jazz Pharmaceuticals

INSM and JAZZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INSM and JAZZ compare

Insmed is the larger company, worth 1.7 times as much as Jazz Pharmaceuticals ($27.0B against $15.6B).

Insmed grew revenue faster over the last twelve months (240% versus 13.5% for Jazz Pharmaceuticals).

Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.4% compared with −39.9% at Insmed.

Insmed scores higher on the StockData Score (8 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINSMJAZZ
Size and price
Market cap$27.0B$15.6B
Share price$122.88$239.77
Change, 1 year−35.7%69.2%
Change, 5 years325%93.2%
Beta (5Y)0.830.20
Employees1,6642,890
StockData Score
Total score8 (better)7
Valuation score00
Growth score3 (better)2
Performance score23 (better)
Health score3 (better)2
Dividend score00
Valuation
P/E–78.1×
P/S17.7×3.3× (better)
P/B37.1×3.7× (better)
EV/EBITDA–42.9×
P/FCF–9.6×
FCF yield−2.3%10.4% (better)
Fair value$61.54$108.36
Margin of safety−99.7% (better)−121%
Growth
Revenue growth (TTM)240% (better)13.5%
Revenue growth, 5Y average29.8% (better)12.5%
Profitability
Gross margin84.4%–
Operating margin−37.1%9.0% (better)
Net margin−39.9%4.4% (better)
FCF margin−41.3%34.4% (better)
Return on equity−72.5%5.1% (better)
Return on invested capital–4.5%
Financial health
Debt / equity0.76 (better)1.33
Net debt / EBITDA–6.37
Interest coverage−6.9×–
Current ratio2.86 (better)1.82
Altman Z-score7.51 (better)1.96
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions102%99.2%
Held by insiders0.89%3.4%
Insider net buying, 12 months−$133M−$67.1M (better)
Superinvestors holding11
Short interest, % of float6.5%9.3%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.